Ind-Swift Labs: consolidated PAT jumps 181% YoY to ₹24.68 Cr on sharp margin expansion

Ind-Swift Laboratories' consolidated net profit for Q1 FY27 (quarter ended June 30, 2026) jumped 181% year-on-year to ₹24.68 Cr from ₹8.77 Cr, well ahead of the 25.4% YoY rise in revenue to ₹191.45 Cr (from ₹152.73 Cr). Sequentially, revenue grew 12.8% and PAT rose 63% over Q4 FY26. Standalone tells the same story — PAT of ₹24.44 Cr, up ~201% YoY on revenue of ₹186.08 Cr — the ~20-point gap versus consolidated growth traces to joint-venture consolidation scope rather than any divergence in the underlying operating story.

The gain is almost entirely margin-led: consolidated OPM (EBITDA margin) expanded to roughly 17.5% from just 2.36% a year ago and 9.08% last quarter, with standalone EBITDA at ₹33.32 Cr against ₹8.44 Cr in Q1 FY26 (per the company's own disclosure). Consolidated NPM rose to ~12.9% from 5.24% YoY. A net exceptional loss of ₹0.24 Cr (₹23.58 Lakh, balances written back/off) was booked this quarter versus nil a year ago, but it is too small to move the growth number — adjusted PAT growth is ~184% YoY, effectively unchanged from the reported 181%.

The stock went into the print at ₹237.24, down 3.7% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

There is no analyst consensus or brokerage preview available for this stock, and the company has issued no formal forward guidance on record, so the print can only be judged against its own trend — a clear multi-quarter margin re-rating (OPM: 2.36% → 9.08% → 17.5%) rather than a one-off spike. Management's own note attributes the quarter to higher EBITDA generation but gives no line-by-line driver beyond the EBITDA and PAT figures disclosed. Alongside the results, the board approved sale of a ~10-acre non-operational land parcel in Derabassi for ₹17.50 Cr (to be realised over 9 months) — unconnected to this quarter's operating performance — while the company is separately progressing a ₹137.2 Cr preferential warrant issue to the promoter group and a ₹40 Cr warehouse-construction MoU, pointing to an active capital-raising and capacity-expansion phase running alongside the margin improvement.